Testosterone undecanoate

Medical uses

Testosterone undecanoate is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Side effects

Side effects of testosterone undecanoate include virilization among others.

Anaphylaxis

The Reandron 1000 formulation (Aveed in the United States) contains 1,000 mg of testosterone undecanoate suspended in 4 ml castor oil with benzyl benzoate for solubilization and as a preservative, and is administered by intramuscular injection. As an excipient in Reandron 1000, benzyl benzoate has been reported as a cause of anaphylaxis (a serious life-threatening allergic reaction) in a case in Australia. Bayer includes this report in information for health professionals and recommends that physicians "should be aware of the potential for serious allergic reactions" to preparations of this type. In Australia, reports to the Adverse Drug Reactions Advisory Committee (ADRAC), which evaluates reports of adverse drug reactions for the Therapeutic Goods Administration (TGA), show several reports of allergic reactions since the anaphylaxis case from 2011.

Pharmacology

Pharmacodynamics

Testosterone undecanoate is a prodrug of testosterone and is an androgen and anabolic–androgenic steroid (AAS). That is, it is an agonist of the androgen receptor (AR).

Pharmacokinetics

Testosterone undecanoate has a very long elimination half-life and mean residence time when given as a depot intramuscular injection. Its elimination half-life is 20.9 days and its mean residence time is 34.9 days in tea seed oil, while its elimination half-life is 33.9 days and its mean residence time is 36.0 days in castor oil. These values are substantially longer than those of testosterone enanthate (which, in castor oil, has values of 4.5 days and 8.5 days, respectively).

Testosterone undecaondate has very low bioavailability when taken orally, only about 3-7% in men and 4-10% in women. This bioavailability is increased with food, especially foods containing fat, thus it is typically recommended to be taken with a meal. It is absorbed through the lymphatic system (90-100%) and peak serum levels are reached after about 3-5 hours. From there, plasma levels decline, typically reaching pre-dose levels after 6-12 hours. The elimination half-life via the oral route has been stated to be 1.6 hours, with a mean residence time of 3.7 hours. However, there is a large amount of individual variability in its duration of action. For this reason it is often dosed twice or even three times a day.

Testosterone undecanoate is metabolized partially in the intestinal wall into 5-alpha-dihydrotestosterone undecanoate (DHTU). In the blood, non-specific esterases metabolize testosterone undecanoate into testosterone and DHTU into dihydrotestosterone (DHT). Thus, testosterone undecanoate increases plasma levels of both testerone and DHT. The fact the conversion happens in the blood complicates the accurate measurement of blood levels of testosterone induced by the drug, as the conversion continues to occur while blood samples are being prepared for assay. Ideally, enzyme inhibitors should be used to properly assay the blood testosterone levels induced by testosterone undecanoate.

Chemistry

Testosterone undecanoate, or testosterone 17β-undecanoate, is a synthetic androstane steroid and a derivative of testosterone. It is an androgen ester; specifically, it is the C17β undecylate (undecanoate) ester of testosterone. A related testosterone ester with a similarly very long duration is testosterone buciclate.

The first commercialized preparation of oral testosterone undecanoate had it dissolved in oleic acid. This formulation had to be refrigerated in the pharmacy for reasons of stability and would only last about three months at room temperature. A newer more stable pharmaceutical formulation with castor oil and propylene glycol laurate has since been developed. This new formulation can be stored at room temperature for three years. A novel self-emulsifying formulation of oral testosterone undecanoate in 300-mg capsules for use once per day has been under development.

History

In the late 1970s, testosterone undecanoate was introduced for oral use in Europe, although intramuscular testosterone undecanoate had already been in use in China for several years. Intramuscular testosterone undecanoate was not introduced in Europe and the United States until much later, in the early to mid 2000s and 2014, respectively. Testosterone undecanoate was approved in the United States only in 2014 after three previous rejections due to safety concerns.

Society and culture

Generic names

Testosterone undecanoate is the generic name of the drug and its and . It is also referred to as testosterone undecylate.

Brand names

Testosterone undecanoate is or has been marketed under a variety of brand names, including Andriol, Androxon, Aveed, Cernos Depot, Jatenzo, Kyzatrex, Nebido, Nebido-R, Panteston, Reandron 1000, Restandol, Sustanon 250, Undecanoate 250, and Undestor.

Availability

Oral testosterone undecanoate is available in Europe, Mexico, Asia, and the United States.

Intramuscular testosterone undecanoate has been approved worldwide, including the European Union, Russia, and the United States. Intramuscular testosterone undecanoate is marketed as Nebido in Europe and as Aveed in the United States while oral testosterone undecanoate is marketed as Andriol.

Legal status

Testosterone undecanoate, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act and a schedule IV controlled substance in Canada under the Controlled Drugs and Substances Act.

In March 2019, the US Food and Drug Administration approved testosterone undecanoate (Jatenzo), an oral testosterone capsule to treat men with certain forms of hypogonadism. These men have low testosterone levels due to specific medical conditions, such as genetic disorders like Klinefelter syndrome or tumors that have damaged the pituitary gland. The FDA granted the approval of Jatenzo to Clarus Therapeutics.

In March 2022, testosterone undecanoate (Tlando) was approved for medical use in the United States.

In July 2022, Kyzatrex, an oral testosterone undecanoate capsule, was approved for medical use in the United States. The FDA granted the approval of Kyzatrex to Marius Pharmaceuticals.

Research

Non-alcoholic steatohepatitis

In 2013, a phase II clinical trial testing intramuscular testosterone undecanoate for the treatment of non-alcoholic steatohepatitis (NASH) was initiated in the United Kingdom. In the United States in 2018, Lipocine Inc. began investigating the potential of using an oral testosterone undecanoate formulation, known as LPCN-1144, in patients with NASH.

Osteoporosis

In 2013, a study aimed to evaluate the efficacy of testosterone undecanoate therapy on bone mineral density (BMD) and biochemical markers of bone turnover in elderly males with osteoporosis and low serum testosterone levels.

They study found that administering low-dose testosterone undecanoate (TU) at a rate of 20 mg per day to elderly men with low serum testosterone and osteoporosis effectively increases bone mineral density in the lumbar spine and femoral neck, and improves bone turnover, similar to the standard-dose TU (40 mg, per day) treatment. The treatment did not exhibit any adverse side effects on the prostate gland, including prostate-specific antigen. Therefore, low-dose TU appears to be a safe and cost-effective protocol for treating elderly male osteoporosis. However, further clinical trials with larger sample sizes, multiple centers, and long-term follow-ups are required to determine the efficacy and safety of low-dose testosterone undecanoate treatment in elderly male osteoporosis with low serum testosterone.

Health implications

Risks associated with treatment of late-onset hypogonadism

There is a potential concern in the medical community that the administration of testosterone therapy for the treatment of late-onset hypogonadism may escalate the risks associated with benign prostatic hyperplasia, prostate cancer and heart diseases.

Body composition

In 2020, a study that evaluated the effects of testosterone therapy in men with testosterone deficiency and varying degrees of weight (normal weight, overweight, and obesity) on anthropometric and metabolic parameters found that long-term testosterone undecanoate therapy in hypogonadal men, regardless of their weight at the start of the study, led to improvements in several body composition parameters, including body weight, waist circumference, and body mass index. Additionally, testosterone undecanoate therapy was found to lower fasting blood glucose and HbA1c levels and improve lipid profiles in this population.

Bone density

There have been several studies that evaluate the effect of testosterone therapy on bone density or bone mineral density (BMD). One study concluded that long-term testosterone replacement therapy (TRT) in middle-aged men with late-onset hypogonadism (LOH) and metabolic syndrome (MS) led to a significant increase in both vertebral and femoral bone mineral density (BMD) after 36 months of treatment, as measured by dual-energy x-ray absorptiometry. The TRT treatment was shown to induce a 5% per year increase in BMD without changes in body mass index (BMI). The study suggests that long-term TRT could be beneficial for improving bone health in middle-aged men with LOH and MS, even in the absence of osteoporosis.

References

References

1. (20 August 2019). "Testosterone Use During Pregnancy".
2. (2022-11-04). "Anabolic steroid misuse".
3. (18 October 2022). "Kyzatrex- testosterone undecanoate capsule, liquid filled".
4. (13 January 2010). "Andrology: Male Reproductive Health and Dysfunction". Springer Science & Business Media.
5. (26 July 2012). "Testosterone: Action, Deficiency, Substitution". Cambridge University Press.
6. (2001). "Principles and Practice of Endocrinology and Metabolism". Lippincott Williams & Wilkins.
7. (2011). "Anabolics". Molecular Nutrition LLC.
8. (April 2017). "Testosterone therapy for transgender men". The Lancet. Diabetes & Endocrinology.
9. (September 2007). "Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals". The Journal of Sexual Medicine.
10. (November 2009). "Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals". European Journal of Endocrinology.
11. (28 September 2010). "New Concepts for Human Disorders of Sexual Development". S. Karger AG.
12. (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology.
13. (April 2016). "Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement". The Journal of Clinical Endocrinology and Metabolism.
14. (11 January 2021). "Jatenzo- testosterone undecanoate capsule, liquid filled".
15. (27 March 2019). "FDA approves new oral testosterone capsule for treatment of men with certain forms of hypogonadism". U.S. [[Food and Drug Administration]] (FDA).
16. (November 2003). "A new oral testosterone undecanoate formulation". World Journal of Urology.
17. (August 2022). "Is Oral Testosterone the New Frontier of Testosterone Replacement Therapy?". Cureus.
18. (2012). "Anaphylaxis triggered by benzyl benzoate in a preparation of depot testosterone undecanoate". Case Reports in Medicine.
19. (2016). "Nebido Monograph – Information for Health Care Professionals". [[Bayer]].
20. (28 October 2007). "The Leydig Cell in Health and Disease". Springer Science & Business Media.
21. (May 1999). "Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies". European Journal of Endocrinology.
22. (1986). "Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone". European Journal of Drug Metabolism and Pharmacokinetics.
23. (24 January 2012). "Foye's Principles of Medicinal Chemistry". Lippincott Williams & Wilkins.
24. (April 1986). "Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone". European Journal of Drug Metabolism and Pharmacokinetics.
25. (26 July 2012). "Testosterone: Action, Deficiency, Substitution". Cambridge University Press.
26. (30 March 2017). "Testosterone: From Basic to Clinical Aspects". Springer.
27. (March 2003). "Important effect of food on the bioavailability of oral testosterone undecanoate". Pharmacotherapy.
28. (April 2007). "The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps". Clinical Endocrinology.
29. (December 2011). "Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride". International Journal of Andrology.
30. (4 March 2012). "Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation". Journal of Andrology.
31. (1 January 2001). "Pharmacology of testosterone preparations". Testosterone.
32. (November 2015). "Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials". Future Science OA.
33. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
34. (January 2000). "Index Nominum 2000: International Drug Directory". Taylor & Francis.
35. (2017). "Reference Module in Neuroscience and Biobehavioral Psychology". Elsevier.
36. (21 February 2005). "Testosterone Dreams: Rejuvenation, Aphrodisia, Doping". University of California Press.
37. (26 July 2010). "The Scientific Basis of Urology". CRC Press.
38. (11 November 2015). "Williams Textbook of Endocrinology". Elsevier Health Sciences.
39. (2004). "Testosterone Undecanoate-Schering AG". Drugs in R&D.
40. (7 March 2014). "FDA Approves Aveed Testosterone Jab, with Restrictions".
41. (6 December 2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Science & Business Media.
42. "Testosterone".
43. "Testosterone undecanoate profile and most popular brands in USA".
44. (10 June 2002). "Hormones, Brain and Behavior, Five-Volume Set". Academic Press.
45. (2017). "Testosterone". Springer.
46. (18 March 2010). "Drug Product Database". Health Canada.
47. (21 December 2006). "Drug Abuse Handbook, Second Edition". CRC Press.
48. (5 August 2016). "Pharmacology for Canadian Health Care Practice". Elsevier Health Sciences.
49. "Clarus Therapeutics Receives U.S. FDA Approval of Jatenzo (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men".
50. (28 March 2022). "Tlando- testosterone undecanoate capsule, liquid filled".
51. (21 December 2022). "Drug Approval Package: Kyzatrex Capsules".
52. "Kyzatrex (testosterone undecanoate) FDA Approval History".
53. (25 April 2017). "Pilot Open Study of Testosterone Replacement in Non-alcoholic Steatohepatitis".
54. "Lipocine Inc. - Clinical Trials".
55. (2013). "Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone". International Journal of Endocrinology.
56. (December 2022). "Testosterone treatment of late-onset hypogonadism - benefits and risks". Rev Endocr Metab Disord.
57. (June 2020). "Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study". International Journal of Obesity.
58. (June 2012). "Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study". The Aging Male.